Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:2239-2242

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shorofsky, S. R.
Right arrow Articles by Gold, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shorofsky, S. R.
Right arrow Articles by Gold, M. R.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Pacemakers and Implantable Defibrillators
Related Collections
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrow Ablation/ICD/surgery

(Circulation. 2000;102:2239.)
© 2000 American Heart Association, Inc.


Clinical Investigation and Reports

Effect of Second-Phase Duration on the Strength-Duration Relation for Human Transvenous Defibrillation

Stephen R. Shorofsky, MD, PhD; Michael R. Gold, MD, PhD

From the Department of Medicine, Division of Cardiology, University of Maryland School of Medicine, Baltimore.

Correspondence to Stephen R. Shorofsky, MD, PhD, Division of Cardiology, Room N3W77, University of Maryland Medical System, 22 S Greene St, Baltimore, MD 21201. E-mail sshorofs{at}medicine.umaryland.edu

Background—The mechanism by which biphasic waveforms improve defibrillation efficacy is unclear. In addition, the optimal shape of the biphasic waveforms remains controversial. Animal experiments suggest that prolonging the duration of the second phase longer than the first worsens defibrillation thresholds (DFT). The purpose of this study was to determine the strength-duration relation for the second phase of a biphasic defibrillation waveform in humans.

Methods and Results—This was a prospective, randomized study of biphasic DFT in 36 patients; a uniform dual-coil transvenous lead system was used. In each patient, 3 DFTs were determined with the pulse duration for the second phase of the defibrillation waveform varying between 1 and 18 ms. The duration of the first phase was fixed at 6 ms and the capacitance was 150 µF. There was a significant increase in the leading edge voltage at DFT only when the second-phase pulse duration was decreased to 1 ms. There was no increase in DFT voltage even when the second-phase pulse duration was increased from 2 to 18 ms. Similar relations were observed for stored energy, leading edge current, or phase 2 energy. The normalized average current delivered during phase 2 decreased monotonically with increasing phase 2 duration.

Conclusions—In humans, the biphasic DFT voltage or energy is increased only when the second phase of the waveform is <2 ms. The DFT voltage is insensitive to increasing the second phase of the defibrillator waveform to as long as 18 ms, or 3 times the duration of the first phase of the waveform.


Key Words: defibrillation • death, sudden • ventricles • tachyarrhythmias